Surgery for Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

Mark S. Etherington; Robert E. Roses

doi:10.1055/s-0038-1675758

Digestive Disease Interventions, Table of Contents

Digestive Disease Interventions 2019; 03(01): 030-037
DOI: 10.1055/s-0038-1675758

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Surgery for Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

Mark S. Etherington

¹Division of Endocrine and Oncologic Surgery, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

,

Robert E. Roses

¹Division of Endocrine and Oncologic Surgery, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

› Author Affiliations

Abstract

Gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) arise from endocrine cell types along the luminal gastrointestinal tract and pancreas. Stage and grade are dominant predictors of outcome. Optimal management of localized, lower-grade GEP-NETs involves surgical resection, which is associated with excellent long-term survival. While high-grade disease is almost always associated with rapid disseminated progression, metastatic, well-differentiated GEP-NETs can progress slowly and are compatible with prolonged survival. Management of patients with an advanced spectrum of lower grade disease can include a range of systemic and local therapies and requires multidisciplinary collaboration. While controversy persists regarding the optimal scope and sequencing of therapy, surgical management can have a substantial impact alone or in combination with other therapies.

Keywords

neuroendocrine tumor - liver metastases - metastasectomy

Full Text

References

References
1 Obendorfer S. Karzinoide tumoren des dunndarms. Frankf Z Pathol 1907; (01) 425-429
2 Scholte A. Ein fall von angioma telangiectaticum cutis mit chronischer endocarditis und malignem dünndarmcarcinoid. Beitr Pathol Anat 1931; (86) 440-443
3 Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 901-912
4 Jensen R, Norton J, Oberg K. Neuroendocrine tumors. In: Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 10th edition. Philadelphia: Saunders Elsevier; 2016: 501-541
5 Dasari A, Shen C, Halperin D. , et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3 (10) 1335-1342
6 Grahame-Smith DG. Progress report: the carcinoid syndrome. Gut 1970; 11 (02) 189-192
7 Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315 (11) 663-666
8 Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res 1999; 18 (02) 133-141
9 Stephen JL, Grahame-Smith DG. Treatment of the carcinoid syndrome by local removal of hepatic metastases. Proc R Soc Med 1972; 65 (05) 444-445
10 Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003; 134 (06) 1057-1063 , discussion 1063–1065
11 Azimuddin K, Chamberlain RS. The surgical management of pancreatic neuroendocrine tumors. Surg Clin North Am 2001; 81 (03) 511-525
12 Lloyd R, Osamura R, Klöppel G, Rosai J. , Eds. WHO Classification of Tumours of Endocrine Organs/IARC Classification of Tumours, Volume 10. 4th ed.; Lyon, France: IARC Press; 2017
13 Rindi G, Klöppel G, Alhman H. , et al; all other Frascati Consensus Conference participants; European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449 (04) 395-401
14 Rindi G, Klöppel G, Couvelard A. , et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451 (04) 757-762
15 Strosberg J, Nasir A, Coppola D, Wick M, Kvols L. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 2009; 40 (09) 1262-1268
16 Reubi JC, Kvols LK, Waser B. , et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50 (18) 5969-5977
17 Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997; 8 (10) 1041-1044
18 Ruszniewski P, Ducreux M, Chayvialle JA. , et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39 (02) 279-283
19 Mancuso K, Kaye AD, Boudreaux JP. , et al. Carcinoid syndrome and perioperative anesthetic considerations. J Clin Anesth 2011; 23 (04) 329-341
20 Rinke A, Müller HH, Schade-Brittinger C. , et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27 (28) 4656-4663
21 Caplin ME, Pavel M, Ćwikła JB. , et al; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371 (03) 224-233
22 Neuroendocrine and Adrenal Tumors. (Version 1.2018). NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf . Published 2018. Accessed June 6, 2018
23 Raymond E, Dahan L, Raoul JL. , et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364 (06) 501-513
24 Faivre S, Niccoli P, Castellano D. , et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol 2017; 28 (02) 339-343
25 Pavel ME, Hainsworth JD, Baudin E. , et al; RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378 (9808): 2005-2012
26 Yao JC, Shah MH, Ito T. , et al; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364 (06) 514-523
27 Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303 (21) 1189-1194
28 Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979; 2 (04) 327-334 http://www.ncbi.nlm.nih.gov/pubmed/93982
29 Öberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001; 12 (Suppl. 02) S111-S114
30 Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326 (08) 519-523
31 Medley L, Morel AN, Farrugia D. , et al. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer 2011; 104 (07) 1067-1070
32 Strosberg JR, Fine RL, Choi J. , et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117 (02) 268-275
33 Pavel M, Baudin E, Couvelard A. , et al; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95 (02) 157-176
34 Krenning EP, Kooij PPM, Bakker WH. , et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci 1994; 733 (01) 496-506
35 Strosberg J, El-Haddad G, Wolin E. , et al; NETTER-1 Trial Investigators. Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
36 Imhof A, Brunner P, Marincek N. , et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29 (17) 2416-2423
37 Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 1986; 147 (01) 149-154
38 Rhee TK, Lewandowski RJ, Liu DM. , et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008; 247 (06) 1029-1035
39 Christante D, Pommier S, Givi B, Pommier R. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. Surgery 2008; 144 (06) 885-893 , discussion 893–894
40 Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003; 180 (05) 1379-1384
41 Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P. ; NET-Liver-Metastases Consensus Conference. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB 2015; 17 (01) 29-37
42 Sangro B, Gil-Alzugaray B, Rodriguez J. , et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112 (07) 1538-1546
43 Mayo SC, de Jong MC, Pulitano C. , et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010; 17 (12) 3129-3136
44 Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003; 12 (01) 231-242
45 Jarnagin WR, Gonen M, Fong Y. , et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236 (04) 397-406 , discussion 406–407
46 Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5 (10) 1502-1522
47 Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery 1988; 104 (06) 1011-1017
48 Chamberlain RS, Canes D, Brown KT. , et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 2000; 190 (04) 432-445
49 Elias D, Lasser P, Ducreux M. , et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 2003; 133 (04) 375-382
50 Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197 (01) 29-37
51 Woltering EA, Voros BA, Beyer DT. , et al. Aggressive surgical approach to the management of neuroendocrine tumors: a report of 1,000 surgical cytoreductions by a single institution. J Am Coll Surg 2017; 224 (04) 434-447
52 Fleisher LA, Beckman JA, Brown KA. , et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 2002 guideline). J Am Coll Cardiol 2007; 50 (17) 418-500
53 Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169 (01) 36-42 , discussion 42–43
54 McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108 (06) 1091-1096
55 Osborne DA, Zervos EE, Strosberg J. , et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13 (04) 572-581
56 Graff-Baker AN, Sauer DA, Pommier SJ, Pommier RF. Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients. Surgery 2014; 156 (06) 1369-1376 , discussion 1376–1377
57 Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy?. Surgery 2016; 159 (01) 320-333
58 Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 2009; 96 (02) 175-184
59 Mayo SC, de Jong MC, Bloomston M. , et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 2011; 18 (13) 3657-3665
60 Saxena A, Chua TC, Chu F, Al-Zahrani A, Morris DL. Optimizing the surgical effort in patients with advanced neuroendocrine neoplasm hepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation. Am J Clin Oncol 2012; 35 (05) 439-445
61 Sporn E, Mancini GJ, Khajanchee Y. , et al. Multimodal cytoreduction for carcinoid liver metastases: analysis of a case series with highly advanced disease. Eur Surg 2008; 40 (02) 72-76
62 Taner T, Atwell TD, Zhang L. , et al. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. HPB 2013; 15 (03) 190-195
63 Shindoh J, Truty MJ, Aloia TA. , et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 2013; 216 (02) 201-209
64 Le Treut YP, Grégoire E, Klempnauer J. , et al; For ELITA. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg 2013; 257 (05) 807-815
65 Fan ST, Le Treut YP, Mazzaferro V. , et al. Liver transplantation for neuroendocrine tumour liver metastases. HPB 2015; 17 (01) 23-28
66 Hellman P, Lundström T, Öhrvall U. , et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002; 26 (08) 991-997
67 Hill JS, McPhee JT, McDade TP. , et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 2009; 115 (04) 741-751
68 Kulke MH, Siu LL, Tepper JE. , et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011; 29 (07) 934-943
69 Chung MH, Pisegna J, Spirt M. , et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001; 130 (06) 954-962
70 Libutti S. Everolimus in Patients with Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated with Surgery. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02031536 . Published 2014
71 Cloyd JM, Omichi K, Mizuno T. , et al. Preoperative fluorouracil, doxorubicin, and streptozocin for the treatment of pancreatic neuroendocrine liver metastases. Ann Surg Oncol 2018; 25 (06) 1709-1715
72 Kaemmerer D, Prasad V, Daffner W. , et al. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 2009; 15 (46) 5867-5870
73 Stoeltzing O, Loss M, Huber E. , et al. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 2010; 395 (02) 185-192
74 van Vliet EI, van Eijck CH, de Krijger RR. , et al. Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med 2015; 56 (11) 1647-1653